University of Calgary
Calgary, Alberta, Canada
Location status: Recruiting
Location contact
Marc J Poulin
CONTACT
NCT Number: NCT03035851
The estimated annual cost of dementia in Canada is $15 billion, with a projected cumulative economic burden of $800 billion by 2038. Effective prevention of dementia at a population level will need to include lifestyle factors such as promoting higher levels of physical activity. Physical inactivity is a modifiable risk factor for Alzheimer disease (AD) and cognitive decline, but the mechanisms by which physical activity exerts its protective effect on the brain remain unknown. Motivated by the need to develop strategies to prevent and treat AD and related dementias (ADRD), the investigators' overall research goal is to discover why the aging brain develops ADRD. To achieve this goal the investigators adopt a translational physiology approach (i.e., study of physiology from molecule/cell to population) to investigate how exercise improves cognitive performance, and the underlying mechanisms by which exercise prevents and/or slows down age-related declines in brain health and cognition. This approach allows the investigators to determine how physiological function is related to ADRD, with important implications for health. The investigators' prior work demonstrated a significant relationship between fitness, vascular regulation and cognition in older adults free of overt disease. These findings have implications for vascular cognitive impairment and ADRD, in which hypoperfusion and dysregulation of cerebral blood flow are thought to be important pathophysiological factors. The investigators' central hypothesis is that regular aerobic exercise mitigates age-related decreases in vascular function and cerebrovascular reserve, which in turn benefits cognition. Work by the investigators and others has provided the necessary data justifying a randomized controlled trial to evaluate the role of exercise in the prevention of ADRD.
The investigators are well equipped to undertake this trial; the investigators have dedicated institutional support and necessary expertise in vascular regulation, cognition, aging, neuroimaging and genetics.
The overall objective of this proposal is to test an exercise intervention for secondary prevention of ADRD in adults between 50 and 80 years old who are at increased risk for ADRD (with memory impairment symptoms but without dementia). The rationale for this trial is the urgent need for dementia prevention: an exercise intervention, which harnesses a translational physiology framework, holds such promise. The investigators will conduct this trial to determine the effects of aerobic exercise on the development of age-associated cognitive decline and dementia. The exercise intervention is designed with input from Alberta Health Services, the universal healthcare provider for Albertans, so that the intervention can be readily adopted into clinical practice if this trial is successful. The trial will address three specific aims.
SPECIFIC AIM 1: Determine the independent effect of exercise on cognitive performance in previously inactive older adults at increased risk of ADRD. The investigators hypothesize that participants randomized to our six-month aerobic exercise intervention will perform better on cognitive tests, compared to control participants randomized to a stretching-toning exercise group.
SPECIFIC AIM 2: Determine underlying biological mechanisms that influence cognitive performance after exercise training. The investigators hypothesize that exercise improves cognition due to changes at molecular/cellular (biomarkers), vascular (cerebral blood flow, cerebrovascular reserve), anatomical and functional (neuroimaging), and behavioural (sleep quality) levels. Further, the investigators hypothesize that ADRD-specific genetic risk scores, reflective of targeted genetic variants, moderate exercise-related cognitive and brain outcomes.
SPECIFIC AIM 3: Determine the extent to which changes in cognition, resting cerebral blood flow and cerebrovascular reserve persist 12 months after participants complete a 6-month exercise training intervention. The investigators hypothesize that the effects of improved aerobic fitness will be maintained over time as a function of persistent lifestyle changes and behavioural support programs. This trial will provide evidence needed to make clinical recommendations for exercise programs in adults at risk for ADRD, with the goal of preventing dementia. Given the investigators' extensive stakeholder input, this intervention will be easily translated to other jurisdictions. This research into the mechanisms of effect for exercise will identify patient subgroups most likely to benefit, surrogate outcome markers for use in future trials to refine intervention dose/duration, and new therapeutic targets for future interventions.
Interested in participating?
Request Info50 year–80 year
All sexes
Interventional
Not applicable
Calgary, Alberta, Canada
Location status: Recruiting
Marc J Poulin
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants must provide a completed PAR-Q+ form (www.csep.ca), the standard method of obtaining physician approval for participation in an exercise program. For participants without a family doctor to provide this form, we will provide information on how to find a family doctor.
Exclusion criteria
Time frame: Measured at baseline, exercise intervention completion (6 months) and follow-up (18 months)
Time frame: Participants will be assessed at baseline, at the completion of the intervention (6 months) and at follow-up (18 months) phases of the study.
Time frame: Participants will be assessed at baseline, at the completion of the intervention (6 months) and at follow-up (18 months) phases of the study.
The change in aerobic fitness will be assessed by VO2max, determined by cardiopulmonary stress testing.
Time frame: Participants will be assessed at baseline, at the completion of the intervention (6 months) and at follow-up (18 months) phases of the study.
blood sampling and analyses of the selected markers (e.g., neurotrophins, cytokines, inflammatory markers, cortisol, oxidative stress, NO and antioxidants).
Time frame: Participants will be assessed at baseline, at the completion of the intervention (6 months) and at follow-up (18 months) phases of the study.
Measures include changes in dietary intake, food frequency, supplement intake, physical activity, cognitive activities, mood changes, social support and engagement.
Time frame: Participants will be assessed at baseline, at the completion of the intervention (6 months) and at follow-up (18 months) phases of the study.
Time frame: Participants will be assessed at baseline, at the completion of the intervention (6 months) and at follow-up (18 months) phases of the study.
Time frame: Participants will be assessed at 6, 12 and 18 months.
The investigators will assess whether, in the 12-month period following the 6-month exercise intervention, individually-tailored, telephone support for home-based exercise improves adherence and sustains the beneficial effects of exercise.
Contact information is provided by the study sponsor or research team.
University of Calgary
Other
Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias: Harnessing Translational Physiology
Acronym: BIMII
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03876314
Alzheimer Disease, Behavior
Greensboro, North Carolina, United States
View Trial DetailsNCT03896711
Alzheimer Disease, Behavior
Baltimore, Maryland, United States
View Trial DetailsNCT02444078
Alzheimer Disease, Behavior
Bruay-sur-l'Escaut, France
View Trial DetailsNCT06291909
Alzheimer Disease, Behavior
Adelaide, South Australia, Australia
View Trial Details